RxDoctor Payments Data

Janelle Townes, MD

Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1801076500

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $38,306 of the $55,599 with a category attached, or 68.9%. 29 manufacturers reported payments, led by Lilly USA, LLC at 39.1% of the total.

$55,599in general payments, 2019–2025

Across 339 payments — averaging $164.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$22K
  • Boehringer Ingelheim$15K
  • Abbott$8K
  • Medtronic$6K
  • Novo Nordisk$1K
  • Amgen$555
  • plus $4K from 23 others

What the payments were for

  • Consulting fees$3501%
  • Speaking & faculty fees$38,30669%
  • Travel & lodging$6,54712%
  • Food & beverage$10,20318%
  • Education$1930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,599 in reported general payments places this provider in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

See all endocrinology, diabetes & metabolism providers in Alabama

Medicare billing

Part B allowed, 2024
$206,019
Medicare patients
271
Services billed
10,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide634$708,876
MounjaroTirzepatide496$558,166
JardianceEmpagliflozin294$241,798
Humulin R U-500 KwikpenInsulin Regular, Human98$163,088
TrulicityDulaglutide143$153,501
Synjardy XrEmpagliflozin/Metformin Hcl161$146,995
RybelsusSemaglutide54$65,611
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro208$59,478
Tresiba Flextouch U-200Insulin Degludec60$50,741
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp242$47,453
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/739$44,175
Trijardy XrEmpaglifloz/Linaglip/Metformin50$40,151
Fiasp FlextouchInsulin Aspart (Niacinamide)60$39,955
KerendiaFinerenone27$38,888
GlyxambiEmpagliflozin/Linagliptin44$36,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Fiasp$1,175$784,517710 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev$21,713$750,190730 claims
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi$14,694$465,486549 claims
BayerKerendia$545$38,88827 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$255$36,04732 claims
MerckJanuvia$242$27,03245 claims
AstraZenecaFarxiga$445$23,42724 claims
AbbVieSynthroid$19$9,955160 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$7,934520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

Other endocrinology, diabetes & metabolism in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →